Raymond Chen and Kathleen O’Malley were selected in the LSIPR 50 2018 publication for their influence on the life sciences industry. They featured in the government and policy section, as LSIPR reports.
In the area of precision medicine, there are questions surrounding what data is needed, how it is used, what it should look like and what concerns there are for patients and society, as Daniel Lim of Kirkland & Ellis reports.
Healthcare investment yields the best returns when focusing on its core aims and forging strong partnerships, James Flynn, managing partner of Deerfield, tells LSIPR.
BMS’s teams are working to answer key questions and more intimately understand the interplay between the immune system and cancer, Paul Golian, vice president and assistant counsel of IP at BMS, tells LSIPR.
Since joining Eli Lilly’s patent division nearly 20 years ago, Manisha Desai has worked on the procurement and enforcement of patents worldwide.
A lack of blood donors and poor healthcare infrastructure inspired Temie Giwa-Tubosun to develop and deliver a life-saving app. LSIPR spoke to the founder of LifeBank.
Marie-Paule Kieny of the Drugs for Neglected Diseases Initiative is on a mission to remind stakeholders and governments that there is a moral imperative to pursue the fight against neglected diseases, as she tells LSIPR.
In order to maximise the value from the patent search process, IP practitioners should take note of several tips including offering clear guidance to the searcher—and even saying ‘thank you’. Ellen Sherin of GQ Life Sciences reports.
Drug companies can take heart from a range of best practices in the battle against counterfeit medicines, as LSIPR finds out.
With Brexit looming, questions are being asked about the future regulatory relationship between the EU and the UK, with life sciences companies wondering how they will be affected. LSIPR reports.